Bonnefoi, H <br/><br/>
Neoadjuvant treatment with docetaxel plus lapatinib, trastuzumab, or both followed by an anthracycline-based chemotherapy in HER2-positive breast cancer: results of the randomised phase II EORTC 10054 study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  Feb 2015 
 - 325-32 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdu551  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anthracyclines--administration & dosage<br/>Antineoplastic Combined Chemotherapy Protocols--therapeutic use<br/>Breast Neoplasms--drug therapy<br/>Chemotherapy, Adjuvant--methods<br/>Cyclophosphamide--administration & dosage<br/>Docetaxel<br/>Epirubicin--administration & dosage<br/>Female<br/>Fluorouracil--administration & dosage<br/>Humans<br/>Lapatinib<br/>Middle Aged<br/>Neoadjuvant Therapy--methods<br/>Quinazolines--administration & dosage<br/>Receptor, ErbB-2--biosynthesis<br/>Taxoids--administration & dosage<br/>Trastuzumab--administration & dosage